Opt2mise 1

Dr. Bode Webinar


OpT2mise: the largest randomized, controlled study on insulin pump therapy for type 2 diabetes*

36 international centers around the globe
  • Compare the efficacy and safety of pump therapy and multiple injection therapy in patients with type 2 diabetes who had failed to respond to a basal-bolus regimen after active insulin titration.
Primary End-point
  • Between-group difference in mean change in A1C from baseline to 6 months.
  • Δ Pump A1C - Δ MDI A1C.
  • Subjects: 331 adult patients randomized (35-75 years old)
  • Duration: 6 months
  • Location: 36 international centers
  • Results delivered with MiniMed® insulin pump
Patient Population
  • Insulin-taking patients with type 2 diabetes on MDI (>3 injections/day)
  • 8.0% ≤ A1C ≤ 12.0%
  • Insulin dose: 0.7-1.8 units/kg/day
  • Mean SMBG ≥ 2.5 times/day

Aronson R, Cohen O, Conget I, et al. OpT2mise: A randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes. Diabetes Technol There. 2014;16:414-420 doi:10.1089/dia.2013.0363.
*Results achieved do not guarantee results in all prospective new patients; variability as between patients is possible.